VOGX (Vogenx) YoY EBITDA Growth: 37.33% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VOGX Vogenx Inc VOGX
8 GF Score
Price $14.93
View Full Analysis

What is Vogenx YoY EBITDA Growth?

Vogenx VOGX +5.93% 8 YoY EBITDA Growth is 37.33% as of Dec. 2025. GuruFocus rates VOGX with a GF Score™ of 8/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Vogenx's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 37.33%.

Vogenx's EBITDA per Share for the six months ended in Dec. 2025 was $-0.19.

Vogenx YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Vogenx's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vogenx YoY EBITDA Growth Chart

Vogenx Annual Data
Trend Dec24 Dec25
YoY EBITDA Growth
0.00 37.33

Vogenx Semi-Annual Data
Dec24 Dec25
YoY EBITDA Growth 0.00 37.33
VOGX
8GF Score
Vogenx Inc VOGX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vogenx YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Vogenx's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.188--0.3)/ | -0.3 |
=37.33 %

Vogenx's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 ) |
=(-0.188--0.3)/ | -0.3 |
=37.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 37.33% mean?
Vogenx (VOGX) has a YoY EBITDA Growth of 37.33% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Vogenx and its competitors.
Is Vogenx's YoY EBITDA Growth too high?
Vogenx's current YoY EBITDA Growth is 37.33%. Overall, Vogenx has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vogenx's YoY EBITDA Growth compare to ?
Vogenx's YoY EBITDA Growth of 37.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Vogenx and its competitors. Vogenx's current YoY EBITDA Growth is 37.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vogenx stock overvalued right now?
Vogenx (VOGX) has a current YoY EBITDA Growth of 37.33%. The current YoY EBITDA Growth is 37.33%. Vogenx's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Vogenx (VOGX), the current YoY EBITDA Growth is 37.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vogenx Business Description

Comparable Companies
Address 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score

Get the complete analysis for VOGX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.93
Price